Johnson & Johnson (NYSE:JNJ) – Stock analysts at Svb Leerink lifted their FY2019 earnings per share estimates for shares of Johnson & Johnson in a research report issued to clients and investors on Wednesday, October 16th. Svb Leerink analyst D. Antalffy now forecasts that the company will post earnings per share of $8.67 for the year, up from their previous estimate of $8.60. Svb Leerink also issued estimates for Johnson & Johnson’s Q4 2019 earnings at $1.86 EPS, Q1 2020 earnings at $2.38 EPS, Q2 2020 earnings at $2.30 EPS, Q3 2020 earnings at $2.46 EPS, Q4 2020 earnings at $1.97 EPS, FY2020 earnings at $9.12 EPS, FY2021 earnings at $9.96 EPS, FY2022 earnings at $10.91 EPS and FY2023 earnings at $11.91 EPS.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $2.05 EPS.

A number of other analysts have also weighed in on JNJ. Morgan Stanley restated an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a research note on Thursday. Wells Fargo & Co reduced their price objective on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Bank of America restated a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and a consensus price target of $151.18.

NYSE:JNJ opened at $127.70 on Friday. The firm has a market cap of $359.38 billion, a P/E ratio of 15.61, a P/E/G ratio of 2.30 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The firm has a 50-day simple moving average of $130.45 and a two-hundred day simple moving average of $134.76.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is presently 46.45%.

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Trust Advisors LP raised its position in Johnson & Johnson by 61.4% in the 1st quarter. First Trust Advisors LP now owns 523,988 shares of the company’s stock worth $73,248,000 after purchasing an additional 199,277 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Johnson & Johnson in the 1st quarter worth approximately $37,044,000. Bath Savings Trust Co raised its position in Johnson & Johnson by 6.2% in the 2nd quarter. Bath Savings Trust Co now owns 42,275 shares of the company’s stock worth $5,888,000 after purchasing an additional 2,479 shares during the last quarter. Cox Capital Mgt LLC raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Cox Capital Mgt LLC now owns 19,920 shares of the company’s stock valued at $2,774,000 after acquiring an additional 113 shares during the last quarter. Finally, Baystate Wealth Management LLC raised its position in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Baystate Wealth Management LLC now owns 29,643 shares of the company’s stock valued at $4,131,000 after acquiring an additional 372 shares during the last quarter. 72.05% of the stock is currently owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Blockchain

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.